Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.
No abstract available

Keywords: DMARDs (biologic); anti-tnf; epidemiology; outcomes research.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antirheumatic Agents*
  • Biosimilar Pharmaceuticals*
  • Etanercept
  • Humans
  • Registries
  • Treatment Outcome


  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals
  • Etanercept